Hannah Rashdan

Mar 13, 2024 | jamanetwork.com | Adewole S. Adamson |Yevgeniy R. Semenov |Hannah Rashdan

Adjuvant Immunotherapy in Stage II Melanoma—Further Risk Stratification is Needed Currently, most patients with stage IIB and IIC melanoma are treated with surgery and undergo subsequent routine surveillance for disease recurrence by dermatologists. However, the recent US Food and Drug Administration approval of immune checkpoint inhibitors (ICIs) as adjuvant therapy in this population is causing a paradigm shift in the management of patients with localized melanoma.